Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.

Feun LG, Li YY, Wu C, Wangpaichitr M, Jones PD, Richman SP, Madrazo B, Kwon D, Garcia-Buitrago M, Martin P, Hosein PJ, Savaraj N.

Cancer. 2019 Jun 28. doi: 10.1002/cncr.32339. [Epub ahead of print]

PMID:
31251403
2.

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.

Feun LG, Wangpaichitr M, Li YY, Kwon D, Richman SP, Hosein PJ, Savaraj N.

J Hepatocell Carcinoma. 2018 Jan 12;5:9-15. doi: 10.2147/JHC.S153672. eCollection 2018.

3.

A Kinetic Dearomatization Strategy for an Expedient Biomimetic Route to the Bielschowskysin Skeleton.

Scesa P, Wangpaichitr M, Savaraj N, West L, Roche SP.

Angew Chem Int Ed Engl. 2018 Jan 26;57(5):1316-1321. doi: 10.1002/anie.201711780. Epub 2018 Jan 5.

PMID:
29232501
4.

Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.

Li YY, Wu C, Shah SS, Chen SM, Wangpaichitr M, Kuo MT, Feun LG, Han X, Suarez M, Prince J, Savaraj N.

Mol Oncol. 2017 Dec;11(12):1806-1825. doi: 10.1002/1878-0261.12151. Epub 2017 Nov 16.

5.

Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.

Wangpaichitr M, Kandemir H, Li YY, Wu C, Nguyen D, Feun LG, Kuo MT, Savaraj N.

Cell Dev Biol. 2017 Jun;6(2). pii: 183. doi: 10.4172/2168-9296.1000183. Epub 2017 Apr 28.

6.

Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy.

Li YY, Feun LG, Thongkum A, Tu CH, Chen SM, Wangpaichitr M, Wu C, Kuo MT, Savaraj N.

Int J Mol Sci. 2017 Jun 19;18(6). pii: E1297. doi: 10.3390/ijms18061297. Review.

7.

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.

Thongkum A, Wu C, Li YY, Wangpaichitr M, Navasumrit P, Parnlob V, Sricharunrat T, Bhudhisawasdi V, Ruchirawat M, Savaraj N.

Int J Mol Sci. 2017 Jun 1;18(6). pii: E1175. doi: 10.3390/ijms18061175.

8.

Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.

Wangpaichitr M, Wu C, Li YY, Nguyen DJM, Kandemir H, Shah S, Chen S, Feun LG, Prince JS, Kuo MT, Savaraj N.

Oncotarget. 2017 Jul 25;8(30):49275-49292. doi: 10.18632/oncotarget.17568.

9.

Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.

Long Y, Tsai WB, Chang JT, Estecio M, Wangpaichitr M, Savaraj N, Feun LG, Chen HH, Kuo MT.

Oncotarget. 2016 Dec 13;7(50):82658-82670. doi: 10.18632/oncotarget.12308.

10.

Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know.

Bhatia S, Pereira K, Mohan P, Narayanan G, Wangpaichitr M, Savaraj N.

Indian J Radiol Imaging. 2016 Jan-Mar;26(1):81-91. doi: 10.4103/0971-3026.178347.

11.

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.

Li YY, Wu C, Chen SM, Shah SS, Wangpaichitr M, Feun LG, Kuo MT, Suarez M, Prince J, Savaraj N.

Oncotarget. 2016 Apr 5;7(14):17665-80. doi: 10.18632/oncotarget.6882.

12.

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.

Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J, He W, Kuo MT, Feun LG.

Oncotarget. 2015 Mar 20;6(8):6295-309.

13.

Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.

Wangpaichitr M, Wu C, Bigford G, Theodoropoulos G, You M, Li YY, Verona-Santos J, Feun LG, Nguyen DM, Savaraj N.

Anticancer Res. 2014 Dec;34(12):6991-9.

PMID:
25503125
14.

Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.

Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG, Kuo MT.

Mol Cancer Ther. 2013 Nov;12(11):2581-90. doi: 10.1158/1535-7163.MCT-13-0302. Epub 2013 Aug 26.

15.

TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation.

You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM, Feun L.

Mol Cell Biochem. 2013 Feb;374(1-2):181-90. doi: 10.1007/s11010-012-1518-1. Epub 2012 Nov 20.

16.

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.

Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N.

Br J Cancer. 2012 Apr 24;106(9):1481-5. doi: 10.1038/bjc.2012.106.

17.

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells.

Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT, Savaraj N.

Mol Cancer Ther. 2012 Mar;11(3):604-15. doi: 10.1158/1535-7163.MCT-11-0599. Epub 2012 Jan 16.

18.

2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion.

Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N, Lampidis TJ.

Cancer Chemother Pharmacol. 2011 Apr;67(4):899-910. doi: 10.1007/s00280-010-1391-0. Epub 2010 Jul 1.

19.

Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG.

Curr Mol Med. 2010 Jun;10(4):405-12. Review.

20.

The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines.

You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Varona-Santos J, Nguyen DM, Feun L.

Biochem Biophys Res Commun. 2010 Apr 9;394(3):760-6. doi: 10.1016/j.bbrc.2010.03.066. Epub 2010 Mar 17.

21.
22.

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.

Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T, Savaraj N.

Eur J Pharmacol. 2008 Sep 4;591(1-3):124-7. doi: 10.1016/j.ejphar.2008.06.028. Epub 2008 Jun 12.

23.

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.

Wangpaichitr M, Savaraj N, Maher J, Kurtoglu M, Lampidis TJ.

Mol Cancer Ther. 2008 Jun;7(6):1506-13. doi: 10.1158/1535-7163.MCT-07-2334.

24.

Arginine deprivation as a targeted therapy for cancer.

Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N.

Curr Pharm Des. 2008;14(11):1049-57. Review.

25.

Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation.

Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN, Lampidis TJ.

Mol Cancer Ther. 2007 Nov;6(11):3049-58.

26.

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose.

Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ.

Mol Cancer Ther. 2007 Feb;6(2):732-41.

27.

The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.

Savaraj N, Wu C, Kuo MT, You M, Wangpaichitr M, Robles C, Spector S, Feun L.

Drug Target Insights. 2007;2:119-28. Epub 2007 Jun 15.

28.

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N.

Mol Cancer. 2005 Jul 20;4(1):25.

29.

Redox regulation of matrix metalloproteinase gene family in small cell lung cancer cells.

Savaraj N, Wei Y, Unate H, Liu PM, Wu CJ, Wangpaichitr M, Xia D, Xu HJ, Hu SX, Tien Kuo M.

Free Radic Res. 2005 Apr;39(4):373-81.

PMID:
16032782
30.

Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Landy H, Markoe A, Potter P, Lasalle G, Marini A, Savaraj N, Reis I, Heros D, Wangpaichitr M, Feun L.

J Neurooncol. 2004 Mar-Apr;67(1-2):215-20.

PMID:
15072470
31.

Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine.

Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ, Feun L.

Int J Oncol. 2003 Jul;23(1):173-9.

PMID:
12792791
32.
33.

Procollagen-Like Protein as a Molecular Target in the Treatment of Primary Brain Tumor.

Wangpaichitr M, Landy H, Wu CJ, Feun LG, Xu R, Xu J, Savaraj N.

ScientificWorldJournal. 2002 Apr 9;2:125-126. doi: 10.1100/tsw.2002.59. eCollection 2002. No abstract available.

Supplemental Content

Loading ...
Support Center